Abstract
Purpose: The aim of this study is to assess the role of traction bronchiectasis/bronchiolectasis and its progression as a predictor for early fibrosis in interstitial lung abnormalities (ILA).
Methods: Three hundred twenty-seven ILA participants out of 5764 in the Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study who had undergone chest CT twice with an interval of approximately five-years were enrolled in this study. Traction bronchiectasis/bronchiolectasis index (TBI) was classified on a four-point scale: 0, ILA without traction bronchiectasis/bronchiolectasis; 1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion; 2, ILA with mild to moderate traction bronchiectasis; 3, ILA and severe traction bronchiectasis and/or honeycombing. Traction bronchiectasis (TB) progression was classified on a five-point scale: 1, Improved; 2, Probably improved; 3, No change; 4, Probably progressed; 5, Progressed. Overall survival (OS) among participants with different TB Progression Score and between the TB progression group and No TB progression group was also investigated. Hazard radio (HR) was estimated with Cox proportional hazards model.
Results: The higher the TBI at baseline, the higher TB Progression Score (P < 0.001). All five participants with TBI = 3 at baseline progressed; 46 (90 %) of 51 participants with TBI = 2 progressed. TB progression was also associated with shorter OS with statistically significant difference (adjusted HR = 1.68, P < 0.001).
Conclusion: TB progression was visualized on chest CT frequently and clearly. It has the potential to be the predictor for poorer prognosis of ILA.
| Original language | English |
|---|---|
| Article number | 100334 |
| Pages (from-to) | 100334 |
| Journal | European Journal of Radiology Open |
| Volume | 8 |
| DOIs | |
| Publication status | Published - 10 Mar 2021 |
Bibliographical note
Funding text Dr. Nishino reports personal fees from Daiichi Sankyo, from AstraZeneca, grants from Merck investigator studies program, grants from Canon Medical Systems, grants from AstraZeneca, grants from Daiichi Sankyo, personal fees from Roche, outside the submitted work. Publisher Copyright: © 2021 The Author(s)UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Other keywords
- Age Gene/Environment Susceptibility-Reykjavik Study
- Interstitial lung abnormality
- Pulmonary fibrosis
- Traction bronchiectasis
- Usual interstitial pneumonia
Fingerprint
Dive into the research topics of 'Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik Study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver